Loading clinical trials...

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib | Clinical Trials | Clareo Health

RECRUITING

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

A Multicenter, Prospective, Cohort Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimibe Under the Real-World Condition

NCT06314919•Boryung Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia
•Those who are judged to need administration of a fixed-dose combination of pitavastatin/ezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe

Exclusion Criteria

•Those who are taking a fixed-dose combination of pitavastatin/ezetimibe at study enrollment
•Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe
•Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.

Locations (1)

Ewha Womans University Seoul Hospital

Seoul, South Korea

Key Dates

Start Date

March 15, 2024

Primary Completion Date

June 1, 2026

Completion Date

June 1, 2026

Last Updated

September 12, 2025

Enrollment

8,606

ESTIMATED participants

Conditions

Primary HypercholesterolemiaMixed Dyslipidemia

Contacts

Shin-young Oh

CONTACT

+82-2-708-8000 syoh@boryung.co.kr

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

NCT06932705

Mixed Dyslipidemia

View study

RECRUITINGPHASE3

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

NCT06568471

HypercholesterolemiaDyslipidemias+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Inclusion Criteria

Exclusion Criteria

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

A Study in Patients With Mixed Dyslipidemia

QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)